Description of Research Expertise:
Dr. Ruella's laboratory focuses on the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally design innovative combined immunotherapies for relapsing/refractory leukemia and lymphoma.
Dr. Marco Ruella obtained his medical degree with high honors at the University of Torino, Italy, in 2007, and completed his specialization in clinical hematology in 2012. He worked as attending physician at the Hematology and Cell Therapy Division of the Mauriziano Hospital and was Instructor at the Biotechnology School at the University of Torino. From 2012 to 2018 he was post-doctoral fellow and then instructor at the University of Pennsylvania in the Center for Cellular immunotherapies under the mentorship of Drs. Carl June and Saar Gill. From 2017 to 2018 Dr. Ruella served as the Associate Director of Dr. June’s laboratory. In 2018 Dr. Ruella was appointed Assistant Professor in Medicine in the Division of Hematology/Oncology of the Dept. of Medicine of the University of Pennsylvania and Scientific Director of the Lymphoma Program of the Hospital of the University of Pennsylvania.
Dr. Ruella was awarded the inaugural SITC EMD-Serono Cancer Immunotherapy Clinical Fellowship (2014), the AACR-BMS Oncology Fellowship in Clinical Cancer Research (2015), the ASH Scholar Award (2016), a NIH K99-R00 award (2017), the “Paola Campese” Award Leukemia Research (2017) and more recently the Cancer Support Community Award (2018). Dr. Ruella is author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is inventor in several patents on CART therapy.
Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M.: Novel Immunotherapies for T Cell Lymphoma and Leukemia Curr Hematol Malig Rep. : 2018.
Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.: Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 24(10):1499-1503 : 2018.
Ascierto Paolo A, Brugarolas James, Buonaguro Luigi, Butterfield Lisa H, Carbone David, Daniele Bruno, Ferris Robert, Fox Bernard A, Galon Jérôme, Gridelli Cesare, Kaufman Howard L, Klebanoff Christopher A, Melero Ignacio, Nathan Paul, Paulos Chrystal M, Ruella Marco, Sullivan Ryan, Zarour Hassane, Puzanov Igor: Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). Journal for immunotherapy of cancer 6 (1): 69,2018.
Ruella Marco, June Carl H: Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans. Molecular therapy : the journal of the American Society of Gene Therapy 26 (6): 1401-1403,2018.
Bu De-Xiu, Singh Reshma, Choi Eugene E, Ruella Marco, Nunez-Cruz Selene, Mansfield Keith G, Bennett Paul, Barton Nathanial, Wu Qilong, Zhang Jiquan, Wang Yongqiang, Wei Lai, Cogan Shawn, Ezell Tucker, Joshi Shree, Latimer Kellie J, Granda Brian, Tschantz William R, Young Regina M, Huet Heather A, Richardson Celeste J, Milone Michael C: Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget 9 (40): 25764-25780,2018.
B.A. Chabner and D.L.Longo: Chapter on Adoptive Cell Therapies in the book “Cancer Chemotherapy and Biotherapy” Lippincott Williams and Wilkins, 2018 in preparation : 2018.
Singh N, Shi J, June CH, Ruella M.: Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer. Curr Hematol Malig Rep 12 (6): 522-529,2017.
Ruella M, Maude SL, Engels B, Barrett DM, Frey N, Marcucci K, Shestova O., Singh N., Perazzelli J., Christian DA, Haagen D., Lacey SF, Melenhorst JJ, Brogdon J, Young R, Porter DL, June CH, Grupp SA, and Gill S.: Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models American Society of Hematology Annual Meeting, Atlanta, GA : 2017.
Ruella M, Barrett DM, Shestova O, Perazzelli J, Posey A, Kozlowski M, Lacey SF, Melenhorst JJ, June CH, and Gill S: A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor (CAR19) positive cells. American Society of Hematology Annual Meeting, Atlanta, GA : 2017.
Ruella M, Kenderian SS.: Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. BioDrugs 31 (6): 473-481,2017.
View all publications